As­traZeneca eyes rare en­docrinol­o­gy mar­ket with $1.05B buy­out of Amolyt Phar­ma

As­traZeneca is bulk­ing up its late-stage rare dis­ease pipeline by ac­quir­ing Amolyt Phar­ma in a $1.05 bil­lion deal, bring­ing in a drug for “one of the largest known rare dis­eases.”

The Big Phar­ma will buy all of Amolyt’s out­stand­ing shares, worth $800 mil­lion, at deal close. The French biotech could re­ceive a fur­ther $250 mil­lion up­on achiev­ing an undis­closed reg­u­la­to­ry mile­stone, ac­cord­ing to an As­traZeneca re­lease Thurs­day. Amolyt staff will join the com­pa­ny’s rare dis­ease unit, Alex­ion Phar­ma­ceu­ti­cals.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.